Recent advances in the structure-based rational design of TNKSIs.

Human tankyrases 1 and 2 (TNKS1/2) are attractive pharmacological biotargets, especially for the treatment of specific types of cancer. This article provides a fairly comprehensive overview of the structural biology of the TNKS-inhibitor complex and the current medicinal chemistry strategies being used in the structure-based rational design of tankyrase-specific inhibitors.

[1]  S. Aaronson,et al.  Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors. , 2014, Journal of medicinal chemistry.

[2]  R. J. Taylor,et al.  WIKI4, a Novel Inhibitor of Tankyrase and Wnt/ß-Catenin Signaling , 2012, PloS one.

[3]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design , 1997 .

[4]  T. Pihlajaniemi,et al.  Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. , 2013, Journal of medicinal chemistry.

[5]  G. Drewes,et al.  Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.

[6]  L. Lehtiö,et al.  Structural Basis and Selectivity of Tankyrase Inhibition by a Wnt Signaling Inhibitor WIKI4 , 2013, PloS one.

[7]  A. Fallarero,et al.  Homogeneous Screening Assay for Human Tankyrase , 2012, Journal of biomolecular screening.

[8]  H. Bregman,et al.  Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.

[9]  L. Lehtiö,et al.  Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors. , 2014, ACS medicinal chemistry letters.

[10]  E. Dmitrovsky,et al.  Evidence for tankyrases as antineoplastic targets in lung cancer , 2013, BMC Cancer.

[11]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[12]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[13]  H. Dinh,et al.  Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. , 2011, Cancer research.

[14]  Steve Schneider,et al.  Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.

[15]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[16]  P. Nordlund,et al.  Fragment-based ligand design of novel potent inhibitors of tankyrases. , 2013, Journal of medicinal chemistry.

[17]  Xin Huang,et al.  Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor , 2012, PloS one.

[18]  H. Seimiya,et al.  A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. , 2010, Biochemical and biophysical research communications.

[19]  M. D. Lloyd,et al.  Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases. , 2013, ACS medicinal chemistry letters.

[20]  T. Pihlajaniemi,et al.  para‐Substituted 2‐Phenyl‐3,4‐dihydroquinazolin‐4‐ones As Potent and Selective Tankyrase Inhibitors , 2013, ChemMedChem.

[21]  Jim Euchner.  Design , 2014, Catalysis from A to Z.

[22]  J. Weigelt,et al.  Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.

[23]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[24]  Atwood K Cheung,et al.  Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. , 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

[25]  H. Bregman,et al.  Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. , 2013, Journal of medicinal chemistry.

[26]  Peng Zhan,et al.  Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. , 2013, Current medicinal chemistry.

[27]  Catherine Burt,et al.  Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. , 2009, Journal of medicinal chemistry.

[28]  Yan Fang,et al.  XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway , 2013, Journal of experimental & clinical cancer research : CR.

[29]  A. Ashworth,et al.  Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.

[30]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[31]  O. Myklebost,et al.  The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines , 2013, Cancer medicine.

[32]  Sejal Vyas,et al.  New PARP targets for cancer therapy , 2014, Nature Reviews Cancer.

[33]  A. Fallarero,et al.  Screening and structural analysis of flavones inhibiting tankyrases. , 2013, Journal of medicinal chemistry.

[34]  V. Schreiber,et al.  Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.

[35]  L. Lehtiö,et al.  Structural basis of selective inhibition of human tankyrases. , 2012, Journal of medicinal chemistry.

[36]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[37]  E. Fearon.  PARsing the phrase "all in for Axin"- Wnt pathway targets in cancer. , 2009, Cancer cell.

[38]  H. Dinh,et al.  A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.

[39]  L. Lum,et al.  Structure-activity relationship studies of small-molecule inhibitors of Wnt response. , 2009, Bioorganic & medicinal chemistry letters.

[40]  S. Krauss,et al.  A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.

[41]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[42]  Natalia Markova,et al.  Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. , 2010, Journal of medicinal chemistry.

[43]  Xi He,et al.  Destruction of a destructor: a new avenue for cancer therapeutics targeting the Wnt pathway. , 2010, Journal of molecular cell biology.

[44]  S. Krauss,et al.  Tankyrases as drug targets , 2013, The FEBS journal.

[45]  Steve Schneider,et al.  Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. , 2013, ACS medicinal chemistry letters.

[46]  D. Chin,et al.  [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. , 2012, Journal of medicinal chemistry.

[47]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[48]  Nicola J. Richmond,et al.  Validity of ligand efficiency metrics. , 2014, ACS medicinal chemistry letters.

[49]  D. Chin,et al.  Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. , 2013, Journal of medicinal chemistry.

[50]  D. Chin,et al.  Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. , 2013, Journal of medicinal chemistry.